ClinicalTrials.gg
Not yet recruitingNCT07728149Updated Jul 27, 2026

Brain Connectomic Mechanisms of Spinal Manipulative Therapy on LDH Analgesia Based on Multimodal MRI

An interventional study of Active Lever Positioning Manipulation and Sham Lever Positioning Manipulation in Lumbar Disc Herniation, sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Intervertebral Disc Displacement with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Intervertebral Disc Displacement · China.

Planned enrollment
12th of 41
126 · median 90
Started
2026
with 3 others
No phase
35 of 52
9 open now
Primary completion
2027-09
later than 7 of 13 live
Registered
46th of 52
by date
Lead sponsor
4 of 52
The Third Affiliated hospital of Zhejiang Chinese Medical University

Among the 52 studies in Intervertebral Disc Displacement with a site in China, this one is the 12th largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2026, is one of 35 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 46th registered.

Intervertebral Disc Displacement

474 studies on the registry are indexed under Intervertebral Disc Displacement; 98 are open to participants now.

Browse Intervertebral Disc Displacement studies →

Open to participants now

13 of the 52 studies in Intervertebral Disc Displacement with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Intervertebral Disc Displacement studies recruiting now, 20 (42%) set no upper age limit and 24 (50%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Intervertebral Disc Displacement with a site in China, or all of them as a file.
02

Study summary

Low back and leg pain caused by lumbar disc herniation (LDH) is common. Lever positioning manipulation (LPM) is a spinal manual therapy used to relieve this pain, but how it affects the brain is unclear. This study will compare active LPM with a sham procedure and use multimodal magnetic resonance imaging (MRI) to investigate changes in brain networks associated with pain relief.

A total of 84 adults with LDH will be randomly assigned in a 1:1 ratio to active LPM or sham LPM, with three sessions per week for 12 weeks. An additional 42 age- and sex-matched healthy adults will undergo baseline assessments without treatment. Participants with LDH will be assessed before treatment, immediately after the first session, at week 6, and at week 12. Outcomes include pain intensity, lumbar function, disability, adverse events, and MRI measures of functional and structural brain connectivity. The study aims to identify brain connectomic mechanisms associated with LPM-induced analgesia.

Read the detailed description

This is a single-center, prospective, randomized, participant- and outcome-assessor-masked, sham-controlled study with a matched healthy control cohort. Eighty-four participants with lumbar disc herniation will be randomly allocated 1:1 to active lever positioning manipulation or sham lever positioning manipulation using a computer-generated block randomization sequence prepared by an independent statistician. Allocation will be concealed in sequentially numbered, opaque, sealed envelopes. Forty-two age- and sex-matched healthy controls will complete baseline clinical and MRI assessments only.

Active and sham treatments will be delivered three times weekly for 12 weeks, with approximately 20 minutes per session. The sham procedure will reproduce the treatment setting, participant position, preparatory procedures, and practitioner contact but will omit the rapid lever-pulling maneuver. Analgesics, neurotrophic drugs, sedatives, spinal manipulation, acupuncture, traction, and other therapies that could affect pain or MRI outcomes will be prohibited during the treatment period.

Participants with LDH will be assessed at baseline before randomization, immediately after the first treatment session, at week 6, and at week 12. The primary outcome is change in pain intensity measured by the Visual Analog Scale from baseline to week 12. Secondary clinical outcomes include lumbar function measured by the Japanese Orthopaedic Association score and disability measured by the Oswestry Disability Index. Multimodal MRI will be used to evaluate longitudinal changes in functional network topology, white-matter structural connectivity, and structure-function coupling. Exploratory analyses will examine gray-matter covariance and associations between clinical improvement and imaging changes. Safety will be assessed through adverse-event monitoring and vital-sign checks at each treatment session.

03

Conditions studied

  • Lumbar Disc Herniation

Keywords

  • Lever Positioning Manipulation
  • Multimodal MRI
  • Brain Connectome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with lumbar disc herniation (LDH):

  • Diagnosis of LDH based on clinical symptoms, physical examination findings, and lumbar imaging consistent with neurological localization; central, paracentral, far-lateral, foraminal, or subarticular lumbar disc protrusion.
  • Aged 18-65 years, of either sex, and right-handed.
  • In the non-acute phase of LDH, with symptom duration of more than 2 weeks.
  • Visual Analog Scale (VAS) score greater than 4 and Japanese Orthopaedic Association (JOA) score less than 15.
  • No use of analgesics, neurotrophic drugs, or sedatives within 1 month before enrollment.
  • No systematic treatment, spinal manipulation, or other physical therapies within 1 month before enrollment.
  • Able to understand the study procedures and complete clinical assessments and MRI scans.
  • Provides written .

Healthy controls:

  • Aged 18-65 years, of either sex, and right-handed.
  • No history of LDH or chronic low back pain.
  • No current pain condition requiring treatment.
  • No neurological or psychiatric disorders.
  • No known structural brain abnormalities.
  • No MRI .
  • Able to complete clinical assessments and MRI scans.
  • Provides written informed consent.

Exclusion criteria

Exclusion Criteria:

Patients with LDH:

  • Low back pain or sciatica caused by conditions other than LDH.
  • Lumbar spondylolisthesis, lumbar tumor, spinal tuberculosis, severe osteoporosis, or localized lumbar skin lesions that may interfere with treatment.
  • Severe cardiovascular, cerebrovascular, hepatic, renal, hematopoietic, neurological, or psychiatric disease.
  • History of severe head trauma, loss of consciousness, or known structural brain abnormality.
  • Impaired consciousness, severe visual or hearing impairment, speech disorder, or inability to complete clinical assessments.
  • Non-MRI-compatible metal implants, implanted electronic devices, cardiac pacemakers, severe claustrophobia, or inability to tolerate MRI scanning.
  • Asymptomatic LDH.
  • Pregnancy, lactation, or planned pregnancy during the study period.
  • Participation in another clinical trial within the previous 3 months.
  • Any condition judged by the investigators to make the patient unsuitable for participation.

Healthy controls:

  • Any condition that may affect eligibility, MRI safety, or data quality.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Active Lever Positioning Manipulation

    Participants with lumbar disc herniation receive active lever positioning manipulation three times per week for 12 weeks, approximately 20 minutes per session. The procedure includes segment localization, stabilization, positioning to the pre-thrust point, and a rapid lever-pulling maneuver during exhalation.

    Procedure: Active Lever Positioning Manipulation

  • Sham comparator
    Sham Lever Positioning Manipulation

    Participants with lumbar disc herniation receive sham lever positioning manipulation three times per week for 12 weeks, approximately 20 minutes per session. The sham procedure reproduces the treatment setting, position, preparatory procedures, and practitioner contact but omits the rapid lever-pulling maneuver.

    Procedure: Sham Lever Positioning Manipulation

  • No intervention
    Matched Healthy Controls

    Age- and sex-matched healthy adults undergo baseline clinical assessment and multimodal MRI only. They receive no study intervention and provide a reference for baseline brain connectivity measures.

Interventions

  • ProcedureActive Lever Positioning Manipulation

    Delivered three times weekly for 12 weeks, approximately 20 minutes per session, by an experienced rehabilitation practitioner. With the participant's hips and knees flexed and legs crossed, the practitioner identifies the target lumbar segment, stabilizes it with the elbow, holds the ankles, and lifts and pulls the legs upward and inward to the pre-thrust position. A rapid lever-pulling maneuver is then performed while the participant exhales.

  • ProcedureSham Lever Positioning Manipulation

    Delivered three times weekly for 12 weeks, approximately 20 minutes per session, in the same setting and position as the active procedure. Preparatory positioning and practitioner contact are reproduced, but no rapid lever-pulling maneuver is performed. The position is held for 30 seconds with a 15-cm elastic lumbar belt placed around the lower abdomen and pelvis at L4-S1, light hand contact on the ankles, and gradual release.

06

What researchers measure

Primary outcomes

  1. Change in Pain Intensity Measured by the Visual Analog Scale (VAS)

    Pain intensity will be assessed using the Visual Analog Scale (VAS). The prespecified primary endpoint is the between-group difference between active LPM and sham LPM in change from baseline to week 12. VAS will also be collected immediately after the first treatment session and at week 6.

    Time frame: Baseline, immediately after the first treatment session, week 6, and week 12; primary endpoint at week 12

Secondary outcomes

  1. Change in Lumbar Function Measured by the Japanese Orthopaedic Association (JOA) Score

    Lumbar neurological and functional status will be assessed using the Japanese Orthopaedic Association (JOA) score. Change from baseline will be compared between the active LPM and sham LPM groups.

    Time frame: Baseline, immediately after the first treatment session, week 6, and week 12

  2. Change in Disability Measured by the Oswestry Disability Index (ODI)

    Disability related to low back pain will be assessed using the Oswestry Disability Index (ODI), a patient-reported measure of limitations in daily activities. Change from baseline will be compared between the active LPM and sham LPM groups.

    Time frame: Baseline, immediately after the first treatment session, week 6, and week 12

  3. Change in Resting-State Functional Brain Network Topology

    Resting-state functional MRI will be parcellated using the 116-region Automated Anatomical Labeling atlas. Pearson correlation matrices and graph-theoretical metrics reflecting network integration, segregation, and nodal importance will quantify functional topology. Longitudinal change will be compared between active LPM and sham LPM.

    Time frame: Baseline, immediately after the first treatment session, week 6, and week 12; main longitudinal comparison from baseline to week 12

  4. Change in White-Matter Structural Connectivity

    Diffusion tensor imaging will be parcellated with the 116-region Automated Anatomical Labeling atlas. Whole-brain deterministic streamline tractography will generate structural networks. Edges will be weighted by mean fractional anisotropy along streamlines connecting region pairs, with absent connections coded as zero. Longitudinal change will be compared between active LPM and sham LPM.

    Time frame: Baseline, immediately after the first treatment session, week 6, and week 12; main longitudinal comparison from baseline to week 12

  5. Change in Brain Structure-Function Coupling

    Functional and white-matter structural connectivity matrices will use the same 116-region Automated Anatomical Labeling parcellation. For each participant, structure-function coupling will be quantified by the correspondence between functional and structural edge weights across the connectome. Longitudinal change will be compared between active LPM and sham LPM.

    Time frame: Baseline, immediately after the first treatment session, week 6, and week 12; main longitudinal comparison from baseline to week 12

Other outcomes

  1. Change in Group-Level Gray-Matter Structural Covariance Networks

    High-resolution T1-weighted images will be segmented, and gray-matter volume will be extracted for each Automated Anatomical Labeling region. Group-level structural covariance networks will be constructed from interregional covariance in gray-matter volume after adjustment for relevant demographic and anatomical covariates. This exploratory measure will be interpreted at the group level rather than as an individual biomarker.

    Time frame: Baseline, immediately after the first treatment session, week 6, and week 12; exploratory longitudinal comparison from baseline to week 12

  2. Association Between Changes in Connectome Metrics and Clinical Outcomes

    Exploratory Spearman rank correlation analyses will assess whether changes in individual-level functional network topology, white-matter structural connectivity, and structure-function coupling are associated with changes in Visual Analog Scale, Japanese Orthopaedic Association, and Oswestry Disability Index scores. The Benjamini-Hochberg false discovery rate procedure will control for multiple comparisons.

    Time frame: Baseline through week 12; change scores for the main exploratory association calculated from baseline to week 12

  3. Incidence of Adverse Events

    The number and proportion of participants experiencing adverse events will be recorded. Any undesirable medical occurrence will be documented regardless of causal relationship, and severity and relationship to the intervention will be assessed. Vital signs and treatment-related discomfort or safety concerns will be checked at each treatment session; serious adverse events will be reported according to institutional requirements.

    Time frame: From the first treatment session through the end of the 12-week intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Sep 2027, 14 months later.

Of 178 non-industry interventional studies with no phase under Intervertebral Disc Displacement, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 14 months is above that.

Counting every sponsor, half of 191 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 27, 2026
StartEst.
Jul 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07728149
Lead sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University
Responsible party
Lijiang Lv (Principal Investigator, The Third Affiliated hospital of Zhejiang Chinese Medical University) — Principal investigator
First posted
Jul 27, 2026
Start date
Jul 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Lijiang Lv
Contact
lvlijiang0288@163.com
+86-18958107858

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion